Back to top

Image: Bigstock

Can HollyFrontier (HFC) Run Higher on Strong Earnings Estimate Revisions?

Read MoreHide Full Article

HollyFrontier which operates as an independent petroleum refiner in the United States could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well.

These positive earnings estimate revisions suggest that analysts are becoming more optimistic on HFC’s earnings for the coming quarter and year. In fact, consensus estimates have moved sharply higher for both of these time frames over the past four weeks, suggesting that HollyFrontiercould be a solid choice for investors.

Current Quarter Estimates for HFC

In the past 30 days, three estimates have gone higher for HollyFrontier while one has gone lower in the same time period. The trend has been pretty favorable too, with estimates increasing from 70 cents a share 30 days ago, to 79 cents today, a move of 12.9%.

Current Year Estimates for HFC

Meanwhile, HollyFrontier’s current year figures are also looking quite promising, with four estimates moving higher in the past month, compared to none lower. The consensus estimate trend has also seen a boost for this time frame, increasing from $1.24 per share 30 days ago to $1.45 per share today, an increase of 16.9%.

HollyFrontier Corporation Price and Consensus

Bottom Line

The stock has also started to move higher lately, adding 20.7% over the past four weeks, suggesting that investors are starting to take note of this impressive story. So, investors may want to consider this Zacks Rank #3 (Hold) stock to profit in the near future.You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

5 Trades Could Profit "Big-League" from Trump Policies

If the stocks above spark your interest, wait until you look into companies primed to make substantial gains from Washington's changing course.

Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals, tariffs, lower taxes, higher interest rates, and spending surges in defense and infrastructure.

See these buy recommendations now >>

Published in